  
Communications
NB : Si vous utilisez ces documents lors de vos travaux ou présentations, merci de faire référence aux auteurs concernés.
2010
ASCO (Chicago)
2009
ASCO (Orlando)
WCLC (San Francisco)
2008
SIOG 2008 (Montréal) :
 |
Randomized phase II trial of first-line gefitinib, gemcitabine or docetaxel,in Performance Status (PS) 2 or 3 non-small cell lung cancer (NSCLC) patients (IFCT-0301) : Elderly Patients analysis
G. Des Guetz, V. Westeel, L. Baudrin, V. Gounant, B. Lebeau, F. Vaylet, T. Urban, F. Barlesi, D. Moro-Sibilot, P.J. Souquet, D. Debieuvre, D. Braun, G. Fraboulet, K. Chouahnia, F. Morin, J.F. Morère
|
ASCO 2008 (Chicago) :
2 communications orales
Bio-IFCT-0002 (G. Zalcman)
Use of Ras effector RASSF1A promoter gene methylation and chromosome 9p loss of heterozygosity (LOH) to predict progression-free survival (PFS) in perioperative chemotherapy (CT) phase III trial IFCT-0002 in resectable non-small cell lung cancer
IFCT-9901 PCI (C. Le Péchoux / S. Senan)
Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): Primary endpoint analysis
|
Poster IFCT-0301 :
Randomized phase II trial of first-line gefitinib, gemcitabine or doxetaxel in performance status (PS) 2 or 3 non-small-cell lung cancer (NSCLC) patients
J. F. Morere, V. Westeel, F. Morin, V. Gounant, B. Lebeau, F. Vaylet, F. Barlesi, T. Urban, J. M. Bréchot, D. Moro-Sibilot
|
|
Poster IFCT-0401 Bio :
Gefitinib administered as first-line in non-resectable adenocarcinoma with bronchioloalveolar
carcinoma features (ADC-BAC) : Predictive biomarkers of efficacy and survival
Wislez M, Antoine M, Poulot V, Baudrin L, Morère JF, Pérol M, Souquet PJ, Lebitasy MP, Zalcman G, Coulet F, Cadranel J
|
1st European Lung Cancer Conference (Geneva, Switzerland 23-26 April 2008)
Communication orale (V. Westeel)
Phase III study comparing preoperative (PRE) and periopeative (PERI) chemotherapy (CT) with two different CT regimens in resectable stage I-II non-small cell lung cancer (NSLC) : the IFCT-0002 protocol.
V. Westeel, B. Milleron, E. Quoix, M. Puyraveau, B. Braun, JL. Breton, L. Bigay-Game, JL. Pujol, F. Morin, A. Depierre
CPLF 2008 :
|
Poster IFCT-0301 CPLF Lille :
Analyse des causes d’un performance status bas et impact pronostique :
données d’un essai de phase II multicentrique randomisé (IFCT-0301)
JM. Bréchot, V. Gounant, F. Morin, V. Westeel, B. Lebeau, F. Vaylet, T. Urban, F. Barlesi, D. Moro-Sibilot, P.J. Souquet, D. Debieuvre, J.F. Morère
|
|
Poster IFCT-0401 CPLF Lille :
Amélioration des symptômes respiratoires dans les adénocarcinomes avec composante bronchiolo-alvéolaires (ADC-CBA) non résécables traités par en première ligne par gefitinib : analyse de la qualité de vie dans l’étude clinique IFCT-0401
Morin F, Tran Q, Quoix E, Debove P, Soria JC, Moro-Sibilot D, Souquet PJ, Friard S, Merle P, Cadranel J
|
|
Poster TVN CPLF Lille :
Refonte d’un système d’information clinique et ressources biologiques dans un service hospitalier : Expérience du service de Pneumologie de l’hôpital Tenon (Paris)
F. Morin1, Q. Tran1, P. Boucher2, V. Poulot3, E. Roux3, N. Mathiot3, E. Bertrand3, M. Antoine3, P. Callard3, J. Cadranel3, B. Milleron3
1Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris - France
2Institut National du Cancer (INCa), Boulogne Billancourt - France
3APHP - Hôpital Tenon, Paris - France
|
2007
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.
Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, Janicot H, Westeel V, Gameroff S, Geneve J, Maraninchi D.
J Clin Oncol. 2007 Sep 1;25(25):3945-51.
 Posters WCLC 2007 Séoul
|
P3-069 IFCT0401 trial: Phase II study of gefitinib administered as first-line treatment in nonresectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) – Does disease control on gefitinib affect progression free survival and overall survival in ADC-BAC?
Cadranel J, Quoix E, Debove P, Moro-Sibilot D, Bréchot J-M, Souquet PJ, Soria JC, Morin F, Milleron B |
|
P3-071 Respiratory symptoms improvement in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) treated with gefitinib: Quality of Life analysis of the IFCT-0401 Trial
Morin F, Tran Q, Quoix E, Debove P, Soria JC, Moro-Sibilot D, Souquet PJ, Friard S, Merle P, Cadranel J |
|
P3-070 Concordance of the Determination of EGFR and K-ras Mutations in a Tumor bank obtained by 15 centers in France : a pilot study of the ERMETIC project.
Cadranel J, Poulot V, Rolland E, Mounawar M, Antoine M, Brambilla E, Danel C, Hainaut P, Chouaid C, Michiels S for the ERMETIC group. Assistance Publique – Hôpitaux de Paris (AP-HP), Paris; Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris; International Agency for Research on Cancer (IARC), Lyon; Centre Hospitalo-Universitaire de Grenoble, Grenoble; Institut Gustave Roussy (IGR), Villejuif – France. |
|
P3-118 IFCT-0301 Randomized phase II trial of gefitinib, gemcitabine or docetaxel in Performance Status (PS) 2 or 3 non-small cell lung cancer (NSCLC) patients: analysis of the clinical impact of comorbidities and tumour burden
JM Brechot, V Gounant, F Morin, V Westeel, B Lebeau, F Vaylet, T Urban, F Barlesi, D Moro-Sibilot, JF Morere |
|
Communication orale ASCO Chicago
Phase III Study Comparing a Preoperative (PRE) and a Perioperative (PERI) Chemotherapy with Two Different CT Regimens in Resectable Non-small Cell Lung Cancer (NSCLC): Early Results (IFCT 0002)
B. Milleron, E. Quoix, V. Westeel, M. Puyraveau, D. Braun, J.L. Breton, L. Bigay-Game, J.L.Pujol, F. Morin, A. Depierre |
|
Poster IFCT-0401 ASCO Chicago :
IFCT-0401 TRIAL
PHASE II STUDY OF GEFITINIB ADMINISTERED AS FIRST-LINE IN NON-RESECTABLE ADENOCARCINOMA WITH BRONCHIOLOALVEOLAR FEATURES (ADC-BAC)
J. Cadranel et coll. |
|
Poster bio-IFCT-0401 ASCO Chicago :
IFCT0401-bio trial
Predictive biological markers for disease control (DC) of patients with non-resectable,
adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) treated with gefitinib
M. Wislez et coll.
|
| |
|
 |
Quelques photos de l'ASCO 2007 |
|
Communication orale CPLF Lyon :
Administration du gefitinib en première ligne de traitement à des malades présentant un adénocarcinome pulmonaire avec composante bronchiolo-alvéolaire non résécable
J. Cadranel et coll.
|
|
Poster IFCT-0401 Bio CPLF Lyon :
Recherche de facteurs biologiques prédictifs du contrôle de la maladie chez les patients ayant un adénocarcinome pulmonaire de type bronchiolo-alvéolaire (ADC-CBA) non résécable traité par gefitinib
M. Wislez et coll.
|
2006
|
Poster GFPC-GLOT-IFCT 02-01 ASCO Atlanta :
Induction (ICT) or consolidation chemotherapy (CT) with cisplatin (C) and paclitaxel (P) plus concurrent chemo-radiation (CT/TRT) with cisplatine and vinorelbine (V) for unresectable stage III non small cell lung cancer (NSCLC) patients (pts) : randomized phase II trial
P. Fournel et coll.
|
|
Poster IFCT-0401 ASCO Atlanta :
Phase II of gefitinib (IRESSA) administered as first-line treatment in patients with non-resectable pneumonic-type adenocarcinoma (P-ADC)
J. Cadranel et coll.
|
|
Poster IFCT-0401 ASCO Atlanta :
Pathological and EGFr molecular analyses of tumor-biopsy samples from patients with non-resectable, pneumonic-type adenocarcinoma treated by gefitinib: preliminary results from surgical specimen
M. Antoine et coll.
|
2005
|
Poster IFCT-0202 IASLC Barcelone :
A french survey of the diagnostic and therapeutic management of elderly people with histologically/cytologically confirmed lung cancer
E. Quoix et coll.
|
|
Poster IFCT-0401 IASLC Barcelone :
Phase II of gefitinib (IRESSA) administered as first-line treatment in patients with non-resectable pneumonic-type adenocarcinoma (P-ADC)
J. Cadranel et coll.
|
|
Poster IASLC Barcelone :
False positives of an intensive postoperative follow-up for non-small cell lung cancer (NSCLC)
V. Westeel et coll.
|
Pour effectuer le téléchargement, cliquez sur la publication qui vous intéresse avec le bouton droit de votre souris et choisissez le menu "enregistrer la cible sous". Elle sera sous format Acrobat 6.0. Pour lire ce format, utilisez le logiciel gratuit Acrobat Reader. Il est disponible au niveau du site http://www.adobe.fr à la page de téléchargement.
-
Dernière modification
Jeudi, 12 Mai 2011
|
Communication 